Most patients with coronary heart disease daily take aspirin to prevent heart attacks, strokes and even death.

A primary outcome event of death or thrombotic complication occurred in 19.3 percent of patients in the aspirin group and 20.4 percent of those in the placebo group. The adverse effect of hemorrhage leading to reoperation occurred in 1.8 percent of patients in the aspirin group and 2.1 percent of those in the placebo group; cardiac tamponade occurred in 1.1 and 0.4 percent, respectively.
"Among patients undergoing coronary artery surgery, the administration of preoperative aspirin resulted in neither a lower risk of death or thrombotic complications nor a higher risk of bleeding than that with placebo," authors concluded.
"Our study showed no increased risk of surgical bleeding, or need for blood transfusion so we now have clear evidence that aspirin can be safely continued up to the day of coronary artery surgery," said Professor Myles.
Reference: Paul S. Myles, Julian A. Smith et al. Stopping vs. Continuing Aspirin before Coronary Artery Surgery, N Engl J Med 2016; 374:728-737, DOI: 10.1056/NEJMoa1507688.
Source-Medindia
MEDINDIA













